BI 2536

Catalog No.S1109

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Cited by 63 Publications

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )
Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )
Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	NGLFXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fOVWlEPTB;MD6wNFc4PiEQvF2=	MlHGV2FPT0WU
ACN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLEW2ZKSzVyPUCuNFA5PDNizszN	MYfTRW5ITVJ?
TE-8	NYTsVnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTqO25KSzVyPUCuNFA6PDFizszN	M4O2THNCVkeHUh?=
LC-2-ad	MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfxTWM2OD1yLkCxNFk{KM7:TR?=	MYfTRW5ITVJ?
ALL-PO	M4OxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYH6S3IxUUN3ME2wMlAyOyEQvF2=	M2LPUHNCVkeHUh?=
EW-16	M4S2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwMEGzN\|Yh\|ryP	M1nhXHNCVkeHUh?=
KM12	M4DLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTBwMEGzOFgh\|ryP	MYDTRW5ITVJ?
GI-1	NHzoc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\wTWM2OD1yLkCxN\|g{KM7:TR?=	NGXr[IhUSU6JRWK=
LS-411N	NImxSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkT4TWM2OD1yLkCxOFA4KM7:TR?=	MYDTRW5ITVJ?
ES8	NWX2TplHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DlfmlEPTB;MD6wNVQ6PCEQvF2=	MkPiV2FPT0WU
SNU-C2B	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;RTWM2OD1yLkCxOVI3KM7:TR?=	M4HkbHNCVkeHUh?=
CESS	M3\ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjwV2NKSzVyPUCuNFE3ODJizszN	NETnVHVUSU6JRWK=
697	NV3lPIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTSfWQzUUN3ME2wMlAyPjZ6IN88US=>	MV\TRW5ITVJ?
NCI-H1963	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfWWpFKSzVyPUCuNFE3PzNizszN	Mkf4V2FPT0WU
IA-LM	M1my[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTBwMEG2PFgh\|ryP	M3;y[3NCVkeHUh?=
SW954	NVTQdZVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j1SGlEPTB;MD6wNVcxPSEQvF2=	NEP3SlFUSU6JRWK=
RL95-2	NVXYVHdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTnUFloUUN3ME2wMlAyPzN6IN88US=>	NIjKblRUSU6JRWK=
LXF-289	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojqTWM2OD1yLkCxO\|ch\|ryP	Mn:1V2FPT0WU
OCUB-M	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTBwMEG4NlYh\|ryP	M2n0RnNCVkeHUh?=
RKO	NF7nPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHmTWM2OD1yLkCxPVg4KM7:TR?=	M2X2SHNCVkeHUh?=
LOUCY	NFHVRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoC4TWM2OD1yLkCyNFUh\|ryP	NUGwfmxwW0GQR1XS
NOS-1	NV\QN2lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7LbHlHUUN3ME2wMlAzODl\|IN88US=>	MUnTRW5ITVJ?
A4-Fuk	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfNT4lKSzVyPUCuNFIzOThizszN	NU\qXI86W0GQR1XS
A388	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDCWFZKSzVyPUCuNFIzOjdizszN	MYnTRW5ITVJ?
TE-9	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHSOWdKSzVyPUCuNFIzPjFizszN	MV\TRW5ITVJ?
KURAMOCHI	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LtfmlEPTB;MD6wNlI5PSEQvF2=	NEXGb3NUSU6JRWK=
KALS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITEd3NKSzVyPUCuNFI{OzhizszN	MYDTRW5ITVJ?
HOP-62	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILVVHBKSzVyPUCuNFI1OiEQvF2=	MUTTRW5ITVJ?
RPMI-8402	NX;MPJhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fLdGlEPTB;MD6wNlUxQCEQvF2=	NUDkV3JyW0GQR1XS
TE-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnxdI5KSzVyPUCuNFI2OTJizszN	NV;1NpM4W0GQR1XS
CCRF-CEM	M{XpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LJWmlEPTB;MD6wNlU1OyEQvF2=	NGm3XnhUSU6JRWK=
HUTU-80	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13Pc2lEPTB;MD6wNlYzPCEQvF2=	MYrTRW5ITVJ?
NCI-H1648	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPVTHd{UUN3ME2wMlAzPjR5IN88US=>	M3u5R3NCVkeHUh?=
HCE-4	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fzZWlEPTB;MD6wNlY5OiEQvF2=	MX\TRW5ITVJ?
ETK-1	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwMEK3N\|Yh\|ryP	NVXRNWQ3W0GQR1XS
TE-15	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rCeWlEPTB;MD6wNlc{QCEQvF2=	MV;TRW5ITVJ?
BE-13	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrNfpFKSzVyPUCuNFI4PCEQvF2=	NILSRYtUSU6JRWK=
KE-37	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{X6VmlEPTB;MD6wNlc1OSEQvF2=	NXrSUphMW0GQR1XS
NCI-H1355	M4j5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwMEK3PFMh\|ryP	M3vsTnNCVkeHUh?=
TE-11	M{j2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEizU3lKSzVyPUCuNFI5ODlizszN	MYHTRW5ITVJ?
BL-70	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzYTWM2OD1yLkCyPFU4KM7:TR?=	NWi5cpM3W0GQR1XS
ES6	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwMEK4PFEh\|ryP	NVnwTHdlW0GQR1XS
GT3TKB	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTBwMEK5OVMh\|ryP	NV:wNlNDW0GQR1XS
LB647-SCLC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3RTWM2OD1yLkCzNVk2KM7:TR?=	NEPqW3RUSU6JRWK=
NB13	NFfTc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTBwMEOzNVYh\|ryP	NYfPXVVJW0GQR1XS
ST486	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1iwPGlEPTB;MD6wN\|M{PyEQvF2=	MWLTRW5ITVJ?
NCI-H82	NFy5c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHy5blZKSzVyPUCuNFM{PDNizszN	M2GxUHNCVkeHUh?=
NTERA-S-cl-D1	NILoVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\LOmlEPTB;MD6wN\|M6QSEQvF2=	NFPweZBUSU6JRWK=
ES4	M3;BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILsTnBKSzVyPUCuNFM1PjNizszN	NIXPZ3pUSU6JRWK=
SK-NEP-1	NIn6SolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLGTWM2OD1yLkCzOFk6KM7:TR?=	M3vYSXNCVkeHUh?=
Becker	M4PqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkG5TWM2OD1yLkCzOVU2KM7:TR?=	Mn7HV2FPT0WU
A101D	NV3YS\|Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1v5c2lEPTB;MD6wN\|c1QCEQvF2=	NXzLZohZW0GQR1XS
SK-UT-1	M3S3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHPT\|E6UUN3ME2wMlA{Pzd2IN88US=>	M4[0RXNCVkeHUh?=
SW982	NEK2XW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3kOodKSzVyPUCuNFM4QSEQvF2=	MXnTRW5ITVJ?
TE-10	M4C4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwMESwOFYh\|ryP	MlLLV2FPT0WU
OVCAR-4	NILUZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofYTWM2OD1yLkC0NFU6KM7:TR?=	NETHW3BUSU6JRWK=
KP-N-YS	NHzkXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\PPGlEPTB;MD6wOFA5PSEQvF2=	NHzyXZRUSU6JRWK=
BL-41	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rXZ2lEPTB;MD6wOFEzPSEQvF2=	NWn1endZW0GQR1XS
MZ1-PC	NFrndmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwMESxNlch\|ryP	NWnnPVhzW0GQR1XS
PF-382	M1;MbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TObGlEPTB;MD6wOFE6QCEQvF2=	Mo\xV2FPT0WU
MOLT-13	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV[xb4x2UUN3ME2wMlA1OjN6IN88US=>	MkW0V2FPT0WU
HCC1599	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;XTGFDUUN3ME2wMlA1OjV6IN88US=>	NUC2RotxW0GQR1XS
IST-MEL1	NUDxfpNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHWSppIUUN3ME2wMlA1PDR{IN88US=>	MWXTRW5ITVJ?
LU-139	NUHDUZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\3TWM2OD1yLkC0OFQzKM7:TR?=	MYDTRW5ITVJ?
MS-1	NEPjW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHWTWM2OD1yLkC0O\|AyKM7:TR?=	M1vUNnNCVkeHUh?=
MFH-ino	NXXQSoJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMEWwNFMh\|ryP	MlyzV2FPT0WU
IMR-5	NGfPXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\T[G5KSzVyPUCuNFUxOjFizszN	MkWzV2FPT0WU
TE-5	M4\ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml30TWM2OD1yLkC1NFY{KM7:TR?=	MoTiV2FPT0WU
DJM-1	NFq3O3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfr[mxKSzVyPUCuNFUyPDJizszN	NGmxN3dUSU6JRWK=
NB17	NIrJZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMEWyNFch\|ryP	MljiV2FPT0WU
KARPAS-45	M1i0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYridWdnUUN3ME2wMlA2OzV6IN88US=>	NYHEOHZCW0GQR1XS
TGBC1TKB	NI\UNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFX4cVJKSzVyPUCuNFU1ODVizszN	NWfScJliW0GQR1XS
ML-2	NEP5RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLGTWM2OD1yLkC1OFE1KM7:TR?=	MVjTRW5ITVJ?
no-10	MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYL2dZZlUUN3ME2wMlA2PDd2IN88US=>	NV[zfY5tW0GQR1XS
CTV-1	NETD[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknRTWM2OD1yLkC1OVAzKM7:TR?=	MWHTRW5ITVJ?
SJSA-1	NEjrWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXT[\|BMUUN3ME2wMlA2PTJizszN	MojZV2FPT0WU
HC-1	NH3LUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP1TWM2OD1yLkC1OVk4KM7:TR?=	M3TtVnNCVkeHUh?=
TE-12	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfBTWM2OD1yLkC1OlE{KM7:TR?=	M4nUeXNCVkeHUh?=
KY821	NUftUHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXi4ZnVGUUN3ME2wMlA2PjN{IN88US=>	NHXOdJNUSU6JRWK=
TALL-1	M{ezWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfTTWM2OD1yLkC1O\|A5KM7:TR?=	NVjTV5JjW0GQR1XS
DEL	M2L6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETxXWVKSzVyPUCuNFU4ODlizszN	MkTZV2FPT0WU
TE-6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LVUmlEPTB;MD6wOVczOiEQvF2=	MmPYV2FPT0WU
SK-LMS-1	NUD4VGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvSTWM2OD1yLkC1PFA2KM7:TR?=	NX3ETlBkW0GQR1XS
EW-1	NX3zfnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS1To81UUN3ME2wMlA2QDN5IN88US=>	MWrTRW5ITVJ?
8-MG-BA	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TrSWlEPTB;MD6wOVg2OSEQvF2=	NGjOZWtUSU6JRWK=
NALM-6	NHi3OpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fLS2lEPTB;MD6wOVk4OyEQvF2=	MX3TRW5ITVJ?
LB771-HNC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLvRY5KSzVyPUCuNFU6PzlizszN	NFz1UoVUSU6JRWK=
HT-144	M4q5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TB[mlEPTB;MD6wOlE{KM7:TR?=	MV3TRW5ITVJ?
KM-H2	NGXrSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTBwME[yNlEh\|ryP	NIXM[GFUSU6JRWK=
SF268	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH1R5FqUUN3ME2wMlA3Ojh4IN88US=>	MkjaV2FPT0WU
RS4-11	M33jW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFraPYRKSzVyPUCuNFY{ODRizszN	MX;TRW5ITVJ?
MHH-PREB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLIVodKSzVyPUCuNFY{OTlizszN	MYHTRW5ITVJ?
ATN-1	NU[zTVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHVTWM2OD1yLkC2N\|Q2KM7:TR?=	MoTvV2FPT0WU
BB30-HNC	M120UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rmVGlEPTB;MD6wOlQ{PiEQvF2=	Mlu2V2FPT0WU
CPC-N	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr5TWM2OD1yLkC2OVI1KM7:TR?=	NE\JdGNUSU6JRWK=
NB1	NYHJWHJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M176NmlEPTB;MD6wOlYyOyEQvF2=	MX\TRW5ITVJ?
KS-1	M2Prbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTBwME[3OFgh\|ryP	NWftTWtqW0GQR1XS
RXF393	NEH2ZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHWfmJwUUN3ME2wMlA3PzZ2IN88US=>	NXfUeW1DW0GQR1XS
IST-SL2	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfaTWM2OD1yLkC3NFA1KM7:TR?=	MVzTRW5ITVJ?
GI-ME-N	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzV2RKUUN3ME2wMlA4Ojh4IN88US=>	MmC2V2FPT0WU
VA-ES-BJ	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTsTWM2OD1yLkC3OFc2KM7:TR?=	NFjzc3FUSU6JRWK=
NCI-H1581	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LmOmlEPTB;MD6wO\|Q4QCEQvF2=	NFuzUXlUSU6JRWK=
U-266	NUDTSndGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;UPWZKSzVyPUCuNFc1QTdizszN	M3HZcHNCVkeHUh?=
DMS-114	M{e1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTBwMEe1Nlgh\|ryP	MkPYV2FPT0WU
NCI-H187	NHXLWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\pflhsUUN3ME2wMlA4PzJ4IN88US=>	M3H5cXNCVkeHUh?=
SW962	NE[2OVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTBwMEe4N\|kh\|ryP	NFPuXJlUSU6JRWK=
MONO-MAC-6	NX3OcnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjBUVRKSzVyPUCuNFc6QDZizszN	MVzTRW5ITVJ?
MOLT-16	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;CTWM2OD1yLkC4NVIyKM7:TR?=	NVf1PGdEW0GQR1XS
KNS-42	NUXIZZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFK5d4ZKSzVyPUCuNFgyPjFizszN	MlPOV2FPT0WU
CMK	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnRVJRKSzVyPUCuNFgzOjVizszN	NYDLOJVIW0GQR1XS
Ramos-2G6-4C10	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\0Z2lEPTB;MD6wPFIzPSEQvF2=	NHzGWmZUSU6JRWK=
Daudi	NEXt[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7ITWJTUUN3ME2wMlA5OjV4IN88US=>	NWTZeIlZW0GQR1XS
NCI-H510A	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTBwMEizN\|Yh\|ryP	NHXvd5ZUSU6JRWK=
LB831-BLC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\BTWM2OD1yLkC4OVYyKM7:TR?=	NWnLZYhIW0GQR1XS
HEL	NVHZbJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXzVXRjUUN3ME2wMlA5PjZ6IN88US=>	MWLTRW5ITVJ?
LU-134-A	NHfrUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwMEi3NFgh\|ryP	NXX3eYdtW0GQR1XS
NCI-H1694	NFzzbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTkTWM2OD1yLkC4O\|Q1KM7:TR?=	Mn62V2FPT0WU
KGN	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvxTWM2OD1yLkC4O\|U6KM7:TR?=	MWDTRW5ITVJ?
A253	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonqTWM2OD1yLkC4PFIzKM7:TR?=	M2TnRnNCVkeHUh?=
DG-75	NYSydoMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVyzTIJoUUN3ME2wMlA5QTJ{IN88US=>	MnPJV2FPT0WU
MOLT-4	M1\xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3admdPUUN3ME2wMlA5QTh\|IN88US=>	NWLpe2dqW0GQR1XS
NCI-SNU-5	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTBwMEmyOVgh\|ryP	MkLQV2FPT0WU
ONS-76	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPpSYpKSzVyPUCuNFkzPzZizszN	MoWwV2FPT0WU
NCI-H446	M3rJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LH[2lEPTB;MD6wPVQ3OiEQvF2=	NYnR[W9YW0GQR1XS
COR-L279	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\JTWM2OD1yLkC5OVU3KM7:TR?=	M1\qd3NCVkeHUh?=
Calu-6	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTBwMEm1PVgh\|ryP	NUDDPGhRW0GQR1XS
BC-3	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPqTWM2OD1yLkC5OlYzKM7:TR?=	NEjHdmlUSU6JRWK=
NCI-H2126	NFLGNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwMEm3PVEh\|ryP	M{j5WXNCVkeHUh?=
NCI-H1882	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMEm4NFkh\|ryP	NIX6OIlUSU6JRWK=
BB65-RCC	NXjQZY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3IeXF6UUN3ME2wMlExOjl2IN88US=>	MnOzV2FPT0WU
DU-4475	M3PyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTBwMUC0NFch\|ryP	M1P6NHNCVkeHUh?=
NCI-H526	NGKzWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHZTWM2OD1yLkGwOFQh\|ryP	MWjTRW5ITVJ?
NEC8	NF63WJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTZ[mdKSzVyPUCuNVA2OjVizszN	NYT3eYdTW0GQR1XS
NCI-H1304	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwMUC1PVQh\|ryP	M4HqSHNCVkeHUh?=
L-540	NFXlSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMUC3NFgh\|ryP	MmfhV2FPT0WU
NCI-SNU-16	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTZTWM2OD1yLkGwO\|QzKM7:TR?=	MlfBV2FPT0WU
HD-MY-Z	NWrZTJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTBwMUC4OVYh\|ryP	MofXV2FPT0WU
K-562	NUK0d2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTBwMUC4OVgh\|ryP	M3j1W3NCVkeHUh?=
JAR	NH72dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTBwMUC5NlUh\|ryP	NF3LNpBUSU6JRWK=
MZ2-MEL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1njU2lEPTB;MD6xNVA2KM7:TR?=	M13p[XNCVkeHUh?=
L-363	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHmTWM2OD1yLkGxNFc6KM7:TR?=	NX[0VFZFW0GQR1XS
BV-173	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTBwMUGyOFMh\|ryP	MmOyV2FPT0WU
NCI-H524	NHqx[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LjTmlEPTB;MD6xNVI4PCEQvF2=	MkXvV2FPT0WU
EoL-1-cell	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f0V2lEPTB;MD6xNVY4OiEQvF2=	NIexSnFUSU6JRWK=
K052	NF22VmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rqfGlEPTB;MD6xNVcyOiEQvF2=	NHfE[XRUSU6JRWK=
TK10	NYO0[GFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwMUG3Nlgh\|ryP	NGfxZ5FUSU6JRWK=
KU812	M2n5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLHS2E4UUN3ME2wMlEzODR2IN88US=>	MlLkV2FPT0WU
RPMI-8226	NFTuWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfDOWZKSzVyPUCuNVIxPTJizszN	NGLhdmhUSU6JRWK=
MZ7-mel	M1nyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTBwMUKyN\|ch\|ryP	NFLjSmVUSU6JRWK=
SK-PN-DW	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrnfndvUUN3ME2wMlEzOjh5IN88US=>	NXvYPHJNW0GQR1XS
SR	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzrbIJKSzVyPUCuNVI1PDFizszN	MXnTRW5ITVJ?
RPMI-6666	M2jnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G4NmlEPTB;MD6xNlc1OyEQvF2=	MY\TRW5ITVJ?
no-11	NWLjSmVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3voZ2lEPTB;MD6xNlg3QSEQvF2=	MV7TRW5ITVJ?
EW-3	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1THR2lEPTB;MD6xNlg6OyEQvF2=	MYPTRW5ITVJ?
LAMA-84	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrSWmJTUUN3ME2wMlE{OTh5IN88US=>	NGDCVY1USU6JRWK=
HT	NFe5PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDmTWM2OD1yLkGzOVc1KM7:TR?=	M1z3c3NCVkeHUh?=
KP-N-RT-BM-1	M1TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHMTWM2OD1yLkGzOlEzKM7:TR?=	NVjSdoRkW0GQR1XS
NCI-H747	NFLoPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnO1TWM2OD1yLkGzO{DPxE1?	M4n2NHNCVkeHUh?=
NCCIT	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGezNXFKSzVyPUCuNVM6OzlizszN	M{HFT3NCVkeHUh?=
MLMA	NV;se5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLmSIpKSzVyPUCuNVQyPjdizszN	MY\TRW5ITVJ?
LP-1	NXG4W3hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorwTWM2OD1yLkG0NlQh\|ryP	MVzTRW5ITVJ?
CAL-148	NWXlZ4d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jDZWlEPTB;MD6xOFQ5OyEQvF2=	NGPQenBUSU6JRWK=
GB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjyb4lmUUN3ME2wMlE1PTJ4IN88US=>	M4nUSHNCVkeHUh?=
COR-L88	NYLOU5BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\ldHFKSzVyPUCuNVQ5ODJizszN	NIrvTGJUSU6JRWK=
NKM-1	NXPvRXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nnXWlEPTB;MD6xOFkxPiEQvF2=	NUf6d\|RNW0GQR1XS
NB5	M{Xqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzqN\|ZKSzVyPUCuNVU1PjJizszN	NYq4b4gyW0GQR1XS
SH-4	M{jReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTBwMUW0OlYh\|ryP	NH60fHNUSU6JRWK=
EM-2	M3OzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfQOFZKUUN3ME2wMlE2PDZ5IN88US=>	NWnmOnVOW0GQR1XS
TGBC24TKB	M1\tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLYTWM2OD1yLkG1OlU6KM7:TR?=	Ml7LV2FPT0WU
SCLC-21H	M{jkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUm3N41JUUN3ME2wMlE2PzB{IN88US=>	NVfQNXFuW0GQR1XS
COLO-684	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwMUW3NlEh\|ryP	MWrTRW5ITVJ?
KINGS-1	M4Hwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITVfIVKSzVyPUCuNVU6OSEQvF2=	M2m0eHNCVkeHUh?=
LS-123	M1PsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIL6d4FKSzVyPUCuNVU6OTdizszN	MXfTRW5ITVJ?
MC116	MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mle2TWM2OD1yLkG2NVU5KM7:TR?=	NYHRcHJbW0GQR1XS
SU-DHL-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLNNIVvUUN3ME2wMlE3OjB4IN88US=>	NUTCbm17W0GQR1XS
NCI-H64	M4S3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HwOmlEPTB;MD6xOlM1PyEQvF2=	NW\wboIyW0GQR1XS
HCE-T	NY\BWIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zm[mlEPTB;MD6xOlUxPCEQvF2=	MkHIV2FPT0WU
LOXIMVI	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nUdWlEPTB;MD6xOlk1QSEQvF2=	M1zVR3NCVkeHUh?=
ARH-77	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTrNnZKSzVyPUCuNVc{PzlizszN	M{[1SnNCVkeHUh?=
DOHH-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYX2N5RYUUN3ME2wMlE4Pjd{IN88US=>	MmHjV2FPT0WU
COLO-320-HSR	NID2PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTBwMUixOVQh\|ryP	M1HYVXNCVkeHUh?=
NB6	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rnb2lEPTB;MD6xPFU3PiEQvF2=	NV\5dI1RW0GQR1XS
L-428	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwMUi4NVMh\|ryP	MYjTRW5ITVJ?
SNB75	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4naPWlEPTB;MD6xPFgzPCEQvF2=	NHXCRnVUSU6JRWK=
NCI-H2141	NV71cVEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HJcWlEPTB;MD6xPVAyOSEQvF2=	NH3ORnVUSU6JRWK=
KARPAS-299	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGSybG1KSzVyPUCuNVkzPDFizszN	MUfTRW5ITVJ?
LC4-1	M{j1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\UOFdKSzVyPUCuNVk2ODJizszN	NHTIR5VUSU6JRWK=
UACC-257	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWP0e3VqUUN3ME2wMlE6QTR5IN88US=>	NGrWXldUSU6JRWK=
EVSA-T	MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfDbHY5UUN3ME2wMlIxOzF{IN88US=>	NWjPOG5KW0GQR1XS
JiyoyeP-2003	NV7YS5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwMkC0O\|ch\|ryP	NX7wNXVNW0GQR1XS
NCI-H720	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjVe2tKSzVyPUCuNlA2OjVizszN	Mn\rV2FPT0WU
GAK	NUXvXGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwMkGxPFkh\|ryP	MXTTRW5ITVJ?
HH	NGrM[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j3PGlEPTB;MD6yNVQxPSEQvF2=	NGPpPINUSU6JRWK=
NCI-H1436	NEPmPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHscWVPUUN3ME2wMlIyPDZ2IN88US=>	NWfk[XA3W0GQR1XS
GR-ST	NEnjWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrVelBKSzVyPUCuNlE1QDhizszN	M3LjTnNCVkeHUh?=
BC-1	NGD1NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTBwMkK2NVYh\|ryP	MmnrV2FPT0WU
SIG-M5	NF;nfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn60TWM2OD1yLkKyO\|I4KM7:TR?=	Mkf0V2FPT0WU
NCI-H345	M2SyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjGPXZuUUN3ME2wMlI{QDB3IN88US=>	MYTTRW5ITVJ?
OPM-2	NEfs[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;3TpNGUUN3ME2wMlI{QDh{IN88US=>	NUDhU\|dxW0GQR1XS
LB1047-RCC	M2TJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nSO2lEPTB;MD6yOFQyKM7:TR?=	M4PCT3NCVkeHUh?=
CTB-1	MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonUTWM2OD1yLkK0OFk{KM7:TR?=	MUTTRW5ITVJ?
A3-KAW	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LNbGlEPTB;MD6yOVM1OSEQvF2=	MUfTRW5ITVJ?
SF126	M{T1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojjTWM2OD1yLkK1N\|g{KM7:TR?=	NHzBZZdUSU6JRWK=
KARPAS-422	NGOzbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvGbIU5UUN3ME2wMlI2PDN3IN88US=>	Ml\PV2FPT0WU
MEG-01	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHK2bGNKSzVyPUCuNlU3PzNizszN	NIXnPZhUSU6JRWK=
NCI-H209	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XkXGlEPTB;MD6yOlM4PCEQvF2=	M3f1[3NCVkeHUh?=
SBC-1	NWnYSY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TrZ2lEPTB;MD6yOlUh\|ryP	M4nIb3NCVkeHUh?=
K5	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2S5ZWlEPTB;MD6yOlk5PCEQvF2=	MojnV2FPT0WU
QIMR-WIL	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTBwMkexOVUh\|ryP	NX;I[5Q1W0GQR1XS
NMC-G1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrzRYx[UUN3ME2wMlI5OjF5IN88US=>	M2fJPHNCVkeHUh?=
IST-MES1	NVu4[YtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzsZmJLUUN3ME2wMlI6OjN6IN88US=>	NEDrVG1USU6JRWK=
SW684	NGDUeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4r5TWlEPTB;MD6zNFA1PyEQvF2=	NIDkN5FUSU6JRWK=
MV-4-11	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DxbGlEPTB;MD6zNFc5QCEQvF2=	NHvMUYVUSU6JRWK=
LAN-6	NU\HT49oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvsUlM3UUN3ME2wMlMyPTd{IN88US=>	NYLz[oJ3W0GQR1XS
RH-1	NHjKbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3aT4ZSUUN3ME2wMlMyQDdzIN88US=>	Mn7yV2FPT0WU
CP66-MEL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvVNpcyUUN3ME2wMlMyQDd6IN88US=>	MWTTRW5ITVJ?
EC-GI-10	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XZNWlEPTB;MD6zNlk5PyEQvF2=	NE\tb2xUSU6JRWK=
GDM-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwM{OwOVkh\|ryP	NUP1RW9QW0GQR1XS
IST-SL1	MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLyTWM2OD1yLkO0PVE1KM7:TR?=	M2P5VXNCVkeHUh?=
KMOE-2	NGf0PYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULVSYRJUUN3ME2wMlM2OTd3IN88US=>	NWfhcGw5W0GQR1XS
OS-RC-2	NFHrdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHRTWM2OD1yLkO1OVQ1KM7:TR?=	M1vRZ3NCVkeHUh?=
HDLM-2	NUGxcoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K4OGlEPTB;MD6zO\|gyPCEQvF2=	M4ny[HNCVkeHUh?=
DSH1	NX7UVJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTBwM{i2N\|Eh\|ryP	MVzTRW5ITVJ?
LS-1034	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojjTWM2OD1yLkO4PVU1KM7:TR?=	NHXOVXdUSU6JRWK=
LB373-MEL-D	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTBwM{mxPVch\|ryP	MXTTRW5ITVJ?
GOTO	NU\aPFBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILwdm1KSzVyPUCuOFIyOThizszN	NYrwSFdbW0GQR1XS
MRK-nu-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTBwNEKyNFUh\|ryP	M2e4OnNCVkeHUh?=
SK-MM-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwNEO0OFIh\|ryP	Ml\NV2FPT0WU
BOKU	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTBwNEO3PVIh\|ryP	M3jYNnNCVkeHUh?=
NOMO-1	M2LSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm1Wox4UUN3ME2wMlQ{QDZizszN	MUjTRW5ITVJ?
J-RT3-T3-5	M4O0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzaVIlvUUN3ME2wMlQ1QDd6IN88US=>	M{fJfXNCVkeHUh?=
COLO-668	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnKTWM2OD1yLkS1OlY5KM7:TR?=	NEDKOWZUSU6JRWK=
SF539	NHTpV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTBwNEi2PFQh\|ryP	MV\TRW5ITVJ?
LB2518-MEL	NU\qNpRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwNEm3NFMh\|ryP	M1viR3NCVkeHUh?=
TE-441-T	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fmNmlEPTB;MD61NFEzKM7:TR?=	MYDTRW5ITVJ?
MDA-MB-134-VI	NXHDZ\|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XQ[2lEPTB;MD61NFkzOSEQvF2=	Mkf6V2FPT0WU
SCC-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwNUG4O\|Mh\|ryP	MYXTRW5ITVJ?
KLE	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTBwNUKxO\|Eh\|ryP	NGPvNJVUSU6JRWK=
LB2241-RCC	NYO4XI83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTpWXNFUUN3ME2wMlUzPTJ3IN88US=>	MXTTRW5ITVJ?
NCI-H1417	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3oSnZKSzVyPUCuOVM1OzVizszN	NF[0blhUSU6JRWK=
NCI-H2081	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwNUi2NVEh\|ryP	MUnTRW5ITVJ?
NCI-H1522	NWfzZWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTBwNUmzPFMh\|ryP	M2SydXNCVkeHUh?=
NCI-H889	NVXt[nVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zLdWlEPTB;MD61PVg1PCEQvF2=	NF7LcYJUSU6JRWK=
CGTH-W-1	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jMWGlEPTB;MD62NFc2PSEQvF2=	MlnjV2FPT0WU
EB-3	NFq1SJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHp[lVJUUN3ME2wMlYyOTV\|IN88US=>	M{\3UHNCVkeHUh?=
D-336MG	M1\OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTBwNkG3PVEh\|ryP	MYHTRW5ITVJ?
LC-1F	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvLTWM2OD1yLk[yOVkzKM7:TR?=	MULTRW5ITVJ?
MHH-NB-11	M{nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PMOWlEPTB;MD62N\|gxOSEQvF2=	Mn;DV2FPT0WU
SK-N-FI	NH;LcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHHTWM2OD1yLk[zPVEh\|ryP	NGX3S3lUSU6JRWK=
NCI-H69	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwNkS4O\|kh\|ryP	MWDTRW5ITVJ?
SCH	M4PnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTBwNk[wNlMh\|ryP	M{XSTHNCVkeHUh?=
LS-513	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDTWmgxUUN3ME2wMlY4OjV7IN88US=>	NV;G[VdrW0GQR1XS
CP67-MEL	M3XXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfCcZBSUUN3ME2wMlY4PTl4IN88US=>	MkTWV2FPT0WU
GCIY	NXXmN5NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTBwN{CzOlMh\|ryP	MVrTRW5ITVJ?
SHP-77	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LVWmlEPTB;MD63NFc{PCEQvF2=	NFPtXWpUSU6JRWK=
EHEB	NH;oeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fEb2lEPTB;MD63NVg2PCEQvF2=	NF3D[4dUSU6JRWK=
D-247MG	NFnxO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i3[GlEPTB;MD63N\|I{OiEQvF2=	M1vvNnNCVkeHUh?=
Raji	MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTBwN{S5PFkh\|ryP	MXnTRW5ITVJ?
MPP-89	NVPuPGlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPtb5JKSzVyPUCuO\|U6PzhizszN	M33hRXNCVkeHUh?=
EKVX	M1Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLyb5dKSzVyPUCuO\|kxPzNizszN	NX3ZeYFnW0GQR1XS
HCC2218	NF:1cXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXITWM2OD1yLke5NVMyKM7:TR?=	NYi1XmF5W0GQR1XS
KNS-81-FD	MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jKWGlEPTB;MD64NVAyOSEQvF2=	MXLTRW5ITVJ?
HCC2157	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[3T2VKSzVyPUCuPFQ6PTFizszN	M12ycXNCVkeHUh?=
BT-474	NF;qc\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTBwOEi4OVQh\|ryP	M4Pve3NCVkeHUh?=
NCI-H748	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTBwOUGyJO69VQ>?	Mnm4V2FPT0WU
EW-24	NFHHcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwOUKwNFIh\|ryP	MmXMV2FPT0WU
D-263MG	MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwOUS1NVIh\|ryP	MkDmV2FPT0WU
OMC-1	M3\TR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrvOVJkUUN3ME2wMlk3Ozd\|IN88US=>	NYj3S25LW0GQR1XS
NCI-H2196	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYT4c4dCUUN3ME2wMlk4Pzd5IN88US=>	NW\vVYRtW0GQR1XS
HAL-01	NEfQXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2O0ZmlEPTB;MD65PVg4OiEQvF2=	MoPXV2FPT0WU
NCI-H2107	M{PQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPWZ\|FZUUN3ME2xMlAyQDV2IN88US=>	NUK5SlFuW0GQR1XS
LB996-RCC	NVv5R3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fxTWlEPTB;MT6wPFA2OSEQvF2=	MVHTRW5ITVJ?
NCI-H1395	NIDvcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTxTWM2OD1zLkGwOlch\|ryP	MlTlV2FPT0WU
CHP-126	NX;1d5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPs[IxLUUN3ME2xMlE3OTl7IN88US=>	M4LOe3NCVkeHUh?=
NB69	NWLTNmRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwMk[xOFgh\|ryP	Ml2yV2FPT0WU
CAS-1	M1Phemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHtRYxPUUN3ME2xMlM1OjNzIN88US=>	MX3TRW5ITVJ?
JVM-3	NFS4[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4G1PWlEPTB;MT60O\|g2PSEQvF2=	NFSzdllUSU6JRWK=
DMS-153	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTlWHI5UUN3ME2xMlU4Pjd2IN88US=>	MmDaV2FPT0WU
SK-MEL-2	NYHLS\|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHXTWM2OD1zLkexO\|g6KM7:TR?=	M2fBT3NCVkeHUh?=
NCI-H1155	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\yXoJOUUN3ME2xMlc{Pjd4IN88US=>	M1T4NHNCVkeHUh?=
NCI-H1092	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PkfWlEPTB;MT63OlE5OiEQvF2=	NFvTTnZUSU6JRWK=
LU-165	NHLtTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjjTWM2OD1zLki2OFc3KM7:TR?=	M1HZenNCVkeHUh?=
HL-60	NH3PbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX3[JRiUUN3ME2xMlk6QTB6IN88US=>	MUDTRW5ITVJ?
REH	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\3SmlEPTB;Mj6wNFU5OiEQvF2=	NFLuOVhUSU6JRWK=
JVM-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zobmlEPTB;Mj6wOlE{PSEQvF2=	NVzPR4VzW0GQR1XS
MN-60	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HaUGlEPTB;Mj6xO\|MxQCEQvF2=	M324c3NCVkeHUh?=
SCC-15	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1v0ZmlEPTB;Mj6yNFI4KM7:TR?=	NFT0UWhUSU6JRWK=
SNU-C1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjxZW9IUUN3ME2yMlIyOzR\|IN88US=>	MnjiV2FPT0WU
SK-MEL-1	NFjnVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEOxSJhKSzVyPUKuN\|IxPDdizszN	M37BNHNCVkeHUh?=
TGW	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLX[XRKSzVyPUKuN\|UxOjdizszN	NYnXc4V5W0GQR1XS
CA46	NGWyXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml2wTWM2OD1{Lke1PVY4KM7:TR?=	MmjhV2FPT0WU
NCI-H23	NXjR[HNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXqy[4lrUUN3ME2yMlgxPzlzIN88US=>	NHnhWHlUSU6JRWK=
MMAC-SF	NH\Xeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;DXlNbUUN3ME2yMlg3PjJ6IN88US=>	M1;nXnNCVkeHUh?=
NCI-H2171	NXznXnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfwTWM2OD1\|LkCzOFQ5KM7:TR?=	M{HYZnNCVkeHUh?=
A704	NFe4bo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XLeWlEPTB;Mz6xOFE6PCEQvF2=	NH3Xd\|JUSU6JRWK=
DB	M3vEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\JcGlEPTB;Mz6yOVU4PiEQvF2=	NEfnXWxUSU6JRWK=
NCI-H719	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TQVWlEPTB;Mz6zNFM5PCEQvF2=	MUnTRW5ITVJ?
MC-CAR	NVrzN5plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[1NWlEPTB;Mz61OFgyPyEQvF2=	MkXyV2FPT0WU
SIMA	NHv3cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjKPXlDUUN3ME2zMlU5PDF4IN88US=>	NI\rVVVUSU6JRWK=
SW872	M1\jOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;2UG8{UUN3ME2zMlc5OTBzIN88US=>	MUHTRW5ITVJ?
HCC1187	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XW[mlEPTB;Mz63PFMyPSEQvF2=	M4DibXNCVkeHUh?=
EW-13	M1HNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfnTWM2OD1\|LkizOFE4KM7:TR?=	NVS0bnRFW0GQR1XS
NCI-SNU-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTRwMkG5PVkh\|ryP	NG\UeJdUSU6JRWK=
NCI-H226	NEjrN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{GxOWlEPTB;ND6zN\|YxPiEQvF2=	MlLEV2FPT0WU
RPMI-8866	M2PIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoO3TWM2OD12LkO2NFI6KM7:TR?=	M1PZdHNCVkeHUh?=
OCI-AML2	NHjON\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LjPWlEPTB;ND61OVI{KM7:TR?=	NYGybnA{W0GQR1XS
LU-65	M1nKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLkS\|RVUUN3ME20Mlk{ODN\|IN88US=>	M2mzUXNCVkeHUh?=
SK-N-DZ	NYTkWphOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTVwNkO0OlUh\|ryP	NFfZdJRUSU6JRWK=
NB14	M2mwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF71UJNKSzVyPUWuPVcyOzVizszN	M4H3TXNCVkeHUh?=
COLO-829	NH\mN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXPSZNHUUN3ME22MlM{OzV7IN88US=>	M2[wR3NCVkeHUh?=
MHH-CALL-2	NIHk[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrKOmFKSzVyPU[uOVE2ODhizszN	NWnoU5FzW0GQR1XS
NCI-H1770	M{HRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrrU4FKSzVyPU[uOlY6ODRizszN	NEjIfnBUSU6JRWK=
ECC4	M1TVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTIZ3g1UUN3ME22MlgzOTd7IN88US=>	NV7xV2NKW0GQR1XS
A498	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLZO456UUN3ME22Mlg4OTl{IN88US=>	NYfkb21ZW0GQR1XS
DMS-79	NIHGNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;oNmlzUUN3ME23MlA1PTF{IN88US=>	MX3TRW5ITVJ?
P30-OHK	NXLufWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoqxTWM2OD15LkKxPVA3KM7:TR?=	NF\5NWVUSU6JRWK=
D-502MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DNcGlEPTB;Nz65PFM3KM7:TR?=	MkTvV2FPT0WU
RCC10RGB	Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRThwME[yPEDPxE1?	Mo[4V2FPT0WU
U-698-M	NH3hd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHNTWM2OD16LkK5NlI3KM7:TR?=	M2raOHNCVkeHUh?=
BB49-HNC	NYfLTpBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlu1TWM2OD17LkSyNlY2KM7:TR?=	NGjDO5hUSU6JRWK=
ES1	M4nMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjjW3dCUUN3ME25MlY5QTV4IN88US=>	MWLTRW5ITVJ?
MFM-223	NYfZTm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFyLkm5Nlch\|ryP	M{LYfXNCVkeHUh?=
C2BBe1	NYLYVZBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jsNmlEPTB;MUGuN\|UzOyEQvF2=	MoCwV2FPT0WU
EB2	MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4qwWWlEPTB;MUKuOlg5OSEQvF2=	M1u3WXNCVkeHUh?=
C8166	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXnTWM2OD1zMz64N\|A{KM7:TR?=	NXXLSnl[W0GQR1XS
ES3	MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofCTWM2OD1zMz65PVc4KM7:TR?=	NUizeWd[W0GQR1XS
NCI-H1650	NHrse29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrnXndkUUN3ME2xOk4{PzZ3IN88US=>	Ml\KV2FPT0WU
Mo-T	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXvS3BDUUN3ME2xO{41ODJ7IN88US=>	NYfGfGQzW0GQR1XS
NB7	M1nT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLNTWM2OD1zNz63OFY4KM7:TR?=	NVXYbJJMW0GQR1XS
ES7	M3e2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF7LkW1NFch\|ryP	M3GzRXNCVkeHUh?=
ES5	NGPnSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlX6TWM2OD1{MT63OlcyKM7:TR?=	MWPTRW5ITVJ?
MSTO-211H	MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHKc4dKSzVyPUKxMlg5PThizszN	M1HXdXNCVkeHUh?=
U-87-MG	NXjsVnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13RdGlEPTB;MkWuNVk3PiEQvF2=	MX\TRW5ITVJ?
THP-1	NFvHbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJ7LkeyNFEh\|ryP	M3m2bnNCVkeHUh?=
NB10	NIOyRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTNyLkK2PVQh\|ryP	M1jj[HNCVkeHUh?=
NH-12	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHSzTVdKSzVyPUOzMlIxOTdizszN	MmPCV2FPT0WU
COLO-824	NGCwXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVKxWnNWUUN3ME2zOE4yODB4IN88US=>	NETXd2pUSU6JRWK=
SKM-1	NFfySVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvjTWM2OD1\|Nz64OFIzKM7:TR?=	NHLm[VhUSU6JRWK=
NCI-H1838	NX[4SXZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTN6LkO3PVch\|ryP	MWnTRW5ITVJ?
RL	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O5e2lEPTB;M{muNlQ4PyEQvF2=	MnjaV2FPT0WU
COLO-800	NHHWZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTRyLkC3O\|Mh\|ryP	MYnTRW5ITVJ?
KG-1	M4T3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DsXGlEPTB;NECuPFk2PSEQvF2=	NXX6VGkxW0GQR1XS
TUR	M1\XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTRzLk[zPVkh\|ryP	M13PSXNCVkeHUh?=
LNCaP-Clone-FGC	NWXZWVd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TnVGlEPTB;NEGuPVAyPyEQvF2=	MoDiV2FPT0WU
NCI-H322M	M2rvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTR{LkW5PFQh\|ryP	MlrTV2FPT0WU
LNCaP	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTlzLkOgcm0>	NF\hOVIzPTVyNUG3OC=>
C4-2	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3vTWM2OD16IH7N	NX;LZ2QyOjV3MEWxO\|Q>
JURKAT	NELqfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVPZWnd1OjRiaB?=		NXrMe2c6UUN3ME20NVYvPjZibl2=	M13ES\|I1PTF7OUm1
MOLT-4	MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4LPR\|I1KGh?		NG\uZlZKSzVyPUK4OVMvPSCwTR?=	NUTqfHRMOjR3MUm5PVU>
REH	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4CybVI1KGh?		MlWzTWM2OD1{OEeuOlghdk1?	NHXmeG8zPDVzOUm5OS=>
NALM-6	M4DwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXj4Xo9pOjRiaB?=		NVXqOlJOUUN3ME2zOFM{OCCwTR?=	MlTuNlQ2OTl7OUW=
RS 4;11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfYVWpkOjRiaB?=		NXi4enZEUUN3ME21NVkvODVibl2=	MYCyOFUyQTl7NR?=
697	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYiyOEBp		M{HzN2lEPTB;MkGwO{4yKG6P	MViyOFUyQTl7NR?=
SIL-ALL	NVXORYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVGyOEBp		MYHJR\|UxRTF7OT63O{BvVQ>?	M33aNFI1PTF7OUm1
CEM	M2rwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mly4NlQhcA>?		MWHJR\|UxRTV{LkG4JI5O	NWHofHBzOjR3MUm5PVU>
P12	NWPNfWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3KyXlI1KGh?		M1WyW2lEPTB;M{muNlchdk1?	MYKyOFUyQTl7NR?=
NALM-16	NHTMe\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXiyOEBp		MYHJR\|UxRTl4LkK4JI5O	M3KyXVI1PTF7OUm1
JURKAT	NVvTZnpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\YRlQ5KGh?		M3HkbmlEPTB;MUSuPFQhdk1?	MXSyOFUyQTl7NR?=
MOLT-4	NIjTV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13pdlQ5KGh?		NF[0ZW1KSzVyPUK2MlYhdk1?	M1:2OFI1PTF7OUm1
REH	NE\BbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWm0PEBp		MoTSTWM2OD12ND63NUBvVQ>?	NXPYR4xoOjR3MUm5PVU>
NALM-6	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYLmcWd5PDhiaB?=		MoCwTWM2OD1{Mz6yOkBvVQ>?	NHHLe5YzPDVzOUm5OS=>
RS 4;11	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlLGOFghcA>?		MWnJR\|UxRTF4ND6yPEBvVQ>?	MonrNlQ2OTl7OUW=
697	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlS4OFghcA>?		M4T2N2lEPTB;M{C1MlMhdk1?	M3S4XlI1PTF7OUm1
SIL-ALL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH\1Ro41QCCq		MoX4TWM2OD15ND62NkBvVQ>?	NYe4fodxOjR3MUm5PVU>
CEM	NXjDXG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrWTVg1QCCq		Ml2yTWM2OD1{ND61OUBvVQ>?	MV6yOFUyQTl7NR?=
P12	M3LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWDUb5h{PDhiaB?=		M{X0[2lEPTB;MUiuOFYhdk1?	M{fWTlI1PTF7OUm1
NALM-16	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGSzflM1QCCq		NFT3eVRKSzVyPU[zMlI1KG6P	NVLkU21uOjR3MUm5PVU>
JURKAT	NU\JNIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVq3NkBp		M3WyS2lEPTB;Mz62OUBvVQ>?	MYSyOFUyQTl7NR?=
MOLT-4	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYD6V2l5PzJiaB?=		M1j2ZmlEPTB;Nz6zPUBvVQ>?	M3npZ\|I1PTF7OUm1
REH	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mk\jO\|IhcA>?		MofJTWM2OD1zNj6wNUBvVQ>?	M334OVI1PTF7OUm1
NALM-6	M4LWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXm5V\|V5PzJiaB?=		M1S3fmlEPTB;MT63PEBvVQ>?	NHPXWXYzPDVzOUm5OS=>
RS 4;11	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu3NkBp		M1\rS2lEPTB;ND6zPEBvVQ>?	M4G2W\|I1PTF7OUm1
697	NVf1NnFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[3NkBp		M1jvPWlEPTB;N{SuNlghdk1?	NHvwRoozPDVzOUm5OS=>
SIL-ALL	M37vcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV:3NkBp		MoD1TWM2OD15LkKgcm0>	M1q4U\|I1PTF7OUm1
CEM	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWq3NkBp		MYXJR\|UxRTVwNEKgcm0>	NWTmNlFIOjR3MUm5PVU>
P12	NHSwfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH;z[II4OiCq		M3fQ[mlEPTB;Nj6zO{BvVQ>?	MmTZNlQ2OTl7OUW=
NALM-16	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfmbJNXPzJiaB?=		NGjpXGpKSzVyPUe3Mlc{KG6P	NUPV[IZPOjR3MUm5PVU>
Y79	MYTBdI9xfG:\|aYOgRZN{[Xl?	MYmxMVUxKG6P	MkLwNVIwOjRiaB?=	NF\oVG9FVVOR	NVHYVIlrcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhV	M37GWFI1OzZ4Nk[1
WER-Rb-1	M3zEfWFxd3C2b4Ppd{BCe3OjeR?=	NU\Pe5BNOS13MDDuUS=>	M2XDPFEzNzJ2IHi=	NG\H[HlFVVOR	M3jrd4lv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=>	Mk\zNlQ{PjZ4NkW=
G7	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjQV25KSzVyPUOuN{BvVQ>?	M2HaTlI1OjB2N{Oz
G166	M{\NXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfMdphKSzVyPUeuNEBvVQ>?	NXuwbG11OjR{MES3N\|M>
CB660	NHPne3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XkcWlEPTB;Nj60JI5O	MUKyOFIxPDd\|Mx?=
CB1117	NV3xT5NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFn1TIxKSzVyPUG1MlYhdk1?	M3nrclI1OjB2N{Oz
KB-3-1	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfQd\|lTUUN3ME2xMlQ5KMLzIECuOVMhdk1?	M1fJZVI{QTZ{NES1
KB-8-5-11	NV3adGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDue4J5UUN3ME21MlAyKMLzIEKuNFEhdk1?	MorBNlM6PjJ2NEW=
KB-C-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TZdWlEPTB;MU[uO\|YhyrFiND61NUBvVQ>?	NWjafG5NOjN7NkK0OFU>
KB-V-1	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTJ6MT6yOEDDuSB\|MT61O{BvVQ>?	NYC3SoU3OjN7NkK0OFU>
OVCAR-8	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jmOWlEPTB;Nz6xPUDDuSB\|Lk[wJI5O	NVfDdVF1OjN7NkK0OFU>
NCI-ADR-RES	M{HXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF{N{OuN\|AhyrFiMUmxMlIxKG6P	M4D1N\|I{QTZ{NES1
MCF7	NXLWVW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly3TWM2OD13LkGxJOKyKDFwNEegcm0>	M17tTFI{QTZ{NES1
MCF7-FLV1000	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>?	NIWxTpAzOzl4MkS0OS=>
S1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJ2LkOwJOKyKDRwN{Wgcm0>	NIrTfmgzOzl4MkS0OS=>
S1-M1-80	NIDv[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnrVZI2UUN3ME2yOlEvODZiwsGgOFgvOjVibl2=	M{\Pb\|I{QTZ{NES1
CORL-23/P	M1Xyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvQbGl3UUN3ME20MlM5KMLzIEGuNlUhdk1?	NXHMUlZLOjN7NkK0OFU>
CORL-23/R	M{fGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDBe4JKSzVyPUWuNVYhyrFiMT64N{BvVQ>?	MVeyN\|k3OjR2NR?=
NIH3T3	NGrvO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjnRpVKSzVyPUSwMlYxKMLzIESuPVchdk1?	NVvOdXlkOjN7NkK0OFU>
NIH3T3-G185	M2jrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfTZ\|J5UUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=>	NF:xN2MzOzl4MkS0OS=>
pcDNA-HEK293	M4D5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LENGlEPTB;Mj63OUDDuSByLk[3JI5O	NH\mSnUzOzl4MkS0OS=>
MDR19-HEK293	M1v4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4L2dGlEPTB;OEWuOVAhyrFiMUOuOlchdk1?	NEDsO2kzOzl4MkS0OS=>
R482-HEK293	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXkTWM2OD1{NT65O{DDuSB2Lkm1JI5O	MXmyN\|k3OjR2NR?=
MRP1-HEK293	NIHKRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jYOWlEPTB;Mj65PUDDuSBzLkS5JI5O	NHP3XIMzOzl4MkS0OS=>
SF188	Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3ex[\|ExNTFyMDDuUS=>	MYKyOE06PiCq	MlTISG1UVw>?	MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLTDk[ZBm\GWwdDDtZY5v\XJ?	NX\LdWZsOjN6OEe2OFU>
T98G	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TkPVExNTFyMDDuUS=>	NEXJO4YzPC17NjDo	NVXvSnQ1TE2VTx?=	MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	NFT3XG4zOzh6N{[0OS=>
DU145	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXfEUXNQ	M37BRmlEPTEkiMy2NEBvVQ>?	NGXaSnkzOzh6NESyPC=>
LNCaP	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1y2RmROW09?	M3r4RmlEPTEkiMy3OUBvVQ>?	MWKyN\|g5PDR{OB?=
PC3	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4K5b2ROW09?	MXHJR\|Ux6oj:MUe1JI5O	NGWy[I8zOzh6NESyPC=>
RT4	NEfrS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJ5LkKxJI5O	M3O0UVI{Pzl{NkO5
5637	MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe2bIYyUUN3ME20OU41PyCwTR?=	NEj5V20zOzd7Mk[zPS=>
T24	M4m1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmniTWM2OD15OT6xNkBvVQ>?	NWjtS3B{OjN5OUK2N\|k>
MCF7	MV3GeY5kfGmxbjDBd5NigQ>?	MYGxNFAhdk1?	M2L2b\|EhcA>?	MoPMSG1UVw>?	MorvdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:owrDHdoVjOS{EoGPnb\|EtyqCSc{KsxsBU\XKyaX7hN{wh[W6mwrDXbZNxOg>?	Mlj0NlM4PzB{NES=
KB-V1	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XLTGlEPTB;Mz65NkDPxE1?	M2\yPVI{PTl\|MUm2
Hec50co	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1faU2lEPTB;NTDuUS=>	MkXVNlMyPDZ4OEe=
MDA-MB-468	NYXUcHAxSXCxcITvd4l{KEG\|c3H5	MUmxM\|UwOTBibl2=	M3jVXFI1NzR6L{eyJIg>	NGH4WZBFVVOR	MmLzbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M4f6NVI{OTR2Mkm0
MCF10A	NEPMfpFCeG:ydH;zbZMhSXO\|YYm=	MUWxM\|UwOTBibl2=	MmqzNlQwPDhxN{KgbC=>	NFLTZWdFVVOR	M1;WNolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M3m3cVI{OTR2Mkm0
Huh-7	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGxM\|ExNzFyMD:xNFAxKG6P	MUS0PEBp		Momw[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5	M3\BS\|IzPzR3NUi3
Daoy	Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWxMlg4PS1{NECgcm0>	Mk\pO\|IhcA>?	MlfjSG1UVw>?	NVjJdo1qUUN3ME21JI5O	NGr0blAzOjN7MEK3PS=>
ONS-76	M1WxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf5UmV7OS56N{WtNlQxKG6P	Ml;FO\|IhcA>?	NVvMVWpRTE2VTx?=	MVnJR\|UxRTdwNTDuUS=>	MUCyNlM6ODJ5OR?=
SUM 149	NWfZT5F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSwMVExOCCwTR?=	MUG3NkBp		MVTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	M4P4XVIzOzB7OUO5
MDA-MB-231	NYC0PYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\iNE0yODBibl2=	Ml30O\|IhcA>?		MUPpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	M3y0UlIzOzB7OUO5
HR5	NVfZcJdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHUW5d3OC1zMECgcm0>	NVvVWI5HPzJiaB?=		Mm\ObY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	MlTXNlI{ODl7M{m=
BT-474-M1	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrrOZZEOC1zMECgcm0>	M2e3NFczKGh?		M3;GOYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NXKzNFlyOjJ\|MEm5N\|k>
AU565	NFjDSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LY[\|AuOTByIH7N	NVTwVXBqPzJiaB?=		M2LIUYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MorSNlI{ODl7M{m=
T47D	M4HtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHlZpA3OC1zMECgcm0>	NGq1PYs4OiCq		NUThOoM1cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MkTJNlI{ODl7M{m=
MCF7	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\ONE0yODBibl2=	MVW3NkBp		NIjGNm9qdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	MknPNlI{ODl7M{m=
HCT116p53(+/+)	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnMNVAuOTByMDDuUS=>	MW[yOE81QCCq		NVzyRZRUcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	NELEZm4zOjJ4MkG3NS=>
HCT116p53(-/-)	NF76ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEC5PGkyOC1zMECwJI5O	NXq1foNVOjRxNEigbC=>		NUT5VGlmcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	MYGyNlI3OjF5MR?=
HeLa	NHrYW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEH2dW4yOC1zMECgcm0>	MVe0PEBp	MXvEUXNQ	NYrhSm9EUUN3ME21Nk46KG6P	MoLpNlIxQDB{M{W=
HeLa	NHz2cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;KNVAuOTByIH7N	NITH[IE4OiCq	M1\icGROW09?	MluyTWM2OD13MD61JI5O	M3vl[VIzODhyMkO1
GBC	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV23NkBp		M3jVPGlEPTB;MUSuO\|ghdk1?	M1zTd\|IyQTZ3N{O5
GB-CL-1	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXy3NkBp		NFzwclZKSzVyPUWuNlIhdk1?	NXHiUmVZOjF7NkW3N\|k>
Mz-ChA-2	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXywWIZiPzJiaB?=		M2K2ZmlEPTB;Mz6zNUBvVQ>?	MojzNlE6PjV5M{m=
TGBC1-TKB	NWW3eVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVOxOFQhcA>?		NYrodopOUUN3ME22MlczKG6P	NFjFZnczOTl4NUezPS=>
Wittier	NWn4R5hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWfGZ4U2PzJiaB?=		NG\LXFNKSzVyPUOuNlYhdk1?	M{LZW\|IyQTZ3N{O5
H-1	M3i1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHHyPY84OiCq		MnG3TWM2OD17LkW0JI5O	NGfIRmMzOTl4NUezPS=>
HuH-28	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFSxNIU4OiCq		MnLZTWM2OD1zMT6xPUBvVQ>?	MmPFNlE6PjV5M{m=
NEC	NGXFPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLLN2tOPzJiaB?=		MlHnTWM2OD17Lkm4JI5O	MnXVNlE6PjV5M{m=
REB	M1jFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rvbVczKGh?		M4DMWWlEPTB;MUOuOVEhdk1?	MVSyNVk3PTd\|OR?=
CC-LP-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3mXnk4OiCq		NIHnR4ZKSzVyPUWuPFQhdk1?	M{fZU\|IyQTZ3N{O5
CC-SW-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmntO\|IhcA>?		NV6yNJY3UUN3ME25MlU2KG6P	M1n3ZVIyQTZ3N{O5
EGI-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWXCTFhvPzJiaB?=		NH\t[5dKSzVyPUGwMlczKG6P	NFHG[mgzOTl4NUezPS=>
Sk-ChA-1	NWTFdGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXq5cGpCPzJiaB?=		NXHmblJEUUN3ME2xO{4zKG6P	MmLmNlE6PjV5M{m=
TFK-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGD6WIQ4OiCq		MVzJR\|UxRTF\|LkS1JI5O	MV[yNVk3PTd\|OR?=
786-O	NUfJOnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIW4NVM2NThyIH7N	M{TCdlk3KGh?	MmHDTGNt	MkHXd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	MoXFNlE3PDJ\|N{S=
A498	NWrkXGp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXH5TGxWPS16MDDuUS=>	Mlm3PVYhcA>?	M{XjfmhEdA>?	Ml7sd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	M2HWdVIyPjR{M{e0
ACHN	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDTe4w2NThyIH7N	NHzYdpQ6PiCq	NWjHZXluUEOu	NY\HTYZSe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	NWnzcYM6OjF4NEKzO\|Q>
Caki-1	M{fDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnwOXhVPS16MDDuUS=>	NE\FeZI6PiCq	NUnNcVljUEOu	NYTicpd[e3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MkXiNlE3PDJ\|N{S=
SN12C	NVWzNYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXm1MVgxKG6P	NEfGb2M6PiCq	NHv1PGJJS2x?	MkThd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	MWKyNVY1OjN5NB?=
HMC-1.1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSxMVExODBibl2=	MoPVO\|IhcA>?		NGHTeJVqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	M4Lx[FIyOjR{MUi5
HMC-1.2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTLfWoyNTFyMECgcm0>	NUTYVWlXPzJiaB?=		NF\KR2lqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	MkPDNlEzPDJzOEm=
C2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljVNU0yODByIH7N	NWW0eFNtPzJiaB?=		Mn3MbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	M{S2NlIyOjR{MUi5
CHP-212	M{X5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTDNU0yOjVibl2=	M3XUSFI1NTF{MDDo		MoLibY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NUW1ZYhrOjFzNkmyOFI>
IMR-32	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3T0VFEuOTJ3IH7N	MlnoNlQuOTJyIHi=		MWPpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NIjBS3EzOTF4OUK0Ni=>
Kelly	NHnTTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[3NU0yOjVibl2=	NITMT\|IzPC1zMkCgbC=>		NVnWc5dvcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	NGfhUZkzOTF4OUK0Ni=>
SH-EP	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD1O2EyNTF{NTDuUS=>	NXO1XZZ7OjRvMUKwJIg>		MoDUbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	M4LDW\|IyOTZ7MkSy
SH-SY5Y	NIfHfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuxMVEzPSCwTR?=	NIrOUGwzPC1zMkCgbC=>		MkjybY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	MlfaNlEyPjl{NEK=
SK-N-AS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPScJEyNTF{NTDuUS=>	Mn3RNlQuOTJyIHi=		NEew[W9qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NWnM[nQ3OjFzNkmyOFI>
SK-N-BE	NXqyRlVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3LNU0yOjVibl2=	NH;nT2IzPC1zMkCgbC=>		NFLscGpqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MYCyNVE3QTJ2Mh?=
KG1	NWfKWlNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPROJMyNzFyL{GwNEBvVQ>?	NH20[Gc4OiCq	MWXEUXNQ	MXrpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M2D5cFE6PDV6M{W4
U937	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrGXHp3OS9zMD:xNFAhdk1?	MluxO\|IhcA>?	M4rQfmROW09?	M4TBRYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MXSxPVQ2QDN3OB?=
CAL62	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTDNE4yNTFyMDDuUS=>	M3TCWlczKGh?	NFLuV\|NFVVOR	M1jad2VEPTB;MT60JI5O	NHHaNFkyQTJ{M{W1Ny=>
OCUT-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWwMlEuOTByIH7N	NYLvUJZYPzJiaB?=	MWnEUXNQ	MnXFSWM2OD1{LkOgcm0>	NYDze4J5OTl{MkO1OVM>
8505C	NXrSVoNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TTOFAvOS1zMECgcm0>	M2T6VlczKGh?	NULaSnNiTE2VTx?=	MX7FR\|UxRTNwMjDuUS=>	M2nadVE6OjJ\|NUWz
ACT-1	NHrBb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[3SnRLOC5zLUGwNEBvVQ>?	NVGxdmtrPzJiaB?=	MkTaSG1UVw>?	NYfvNJdGTUN3ME21MlQhdk1?	MmL5NVkzOjN3NUO=
SW1736	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\XTJoxNjFvMUCwJI5O	MkTKO\|IhcA>?	NVfMWXhRTE2VTx?=	MlXGSWM2OD13Lk[gcm0>	NFrEfHAyQTJ{M{W1Ny=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	+ Expand Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00526149	Completed	Breast Cancer\|Endometrial Cancer\|Head and Neck Cancer\|Melanoma (Skin)\|Ovarian Cancer\|Sarcoma	European Organisation for Research and Treatment of Cancer - EORTC	July 2007	Phase 2
NCT00526149	Completed	Breast Cancer\|Endometrial Cancer\|Head and Neck Cancer\|Melanoma (Skin)\|Ovarian Cancer\|Sarcoma	European Organisation for Research and Treatment of Cancer - EORTC	July 2007	Phase 2
NCT02215044	Terminated	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02215044	Terminated	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT00412880	Completed	Carcinoma Small Cell	Boehringer Ingelheim	January 2007	Phase 2
NCT00412880	Completed	Carcinoma Small Cell	Boehringer Ingelheim	January 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products4

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 63 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 63 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)